Innovate Biopharmaceuticals Inc. (INNT) and XOMA Corporation (NASDAQ:XOMA) Contrasting side by side

Since Innovate Biopharmaceuticals Inc. (NASDAQ:INNT) and XOMA Corporation (NASDAQ:XOMA) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation of both companies.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Innovate Biopharmaceuticals Inc. 1 0.00 N/A -0.47 0.00
XOMA Corporation 16 14.02 N/A -0.93 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 demonstrates the return on assets, return on equity and net margins of Innovate Biopharmaceuticals Inc. and XOMA Corporation.

Net Margins Return on Equity Return on Assets
Innovate Biopharmaceuticals Inc. 0.00% 0% -128.6%
XOMA Corporation 0.00% -62.7% -13.5%

Institutional and Insider Ownership

Innovate Biopharmaceuticals Inc. and XOMA Corporation has shares owned by institutional investors as follows: 10.8% and 52.8%. Innovate Biopharmaceuticals Inc.’s share owned by insiders are 0.3%. Comparatively, XOMA Corporation has 9.6% of it’s share owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Innovate Biopharmaceuticals Inc. -3.67% -9.87% -31.82% -54.55% -80.84% -54.55%
XOMA Corporation -7.4% 19.35% 54.35% 50.66% -23.37% 44.35%

For the past year Innovate Biopharmaceuticals Inc. had bearish trend while XOMA Corporation had bullish trend.


XOMA Corporation beats Innovate Biopharmaceuticals Inc. on 5 of the 7 factors.

Innovate Biopharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing autoimmune and inflammation therapeutics. Its late-stage clinical pipeline focuses on addressing unmet needs in diseases, such as celiac disease, inflammatory bowel disease (IBD), and nonalcoholic steatohepatitis (NASH). The company's lead drug candidate, larazotide acetate (INN-202), has successfully met its primary endpoint in a Phase 2b efficacy clinical trial for celiac disease. It is also developing INN-108, which is entering into Phase 2 clinical trials for the treatment of mild to moderate ulcerative colitis. In addition, the company owns the global rights to INN-329, a proprietary formulation of secretin, a peptide hormone used to enhance visualization in magnetic resonance cholangiopancreatography procedures. Innovate Biopharmaceuticals, Inc. was founded in 2012 and is based in Raleigh, North Carolina.

XOMA Corporation discovers, develops, and commercializes antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The companyÂ’s product candidates include X358, a human negative allosteric modulating insulin receptor antibody that is in Phase II proof-of-concept study for the treatment of patients with hypoglycemia due to congenital hyperinsulinism and hypoglycemia in post-bariatric surgery patients; X213, a allosteric inhibitor for the treatment of prolactinoma and anti-psychotic-induced hyperprolactinemia; and X129, a potent fragment of a monoclonal antibody for the treatment of patients with acute severe hypoglycemia. Its preclinical product candidates comprise interleukin 2 for the treatment of metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor, a G-protein-coupled receptor for the treatment of hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies, including Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX. It has research and development collaboration and licensing agreements with Novartis AG; Novo Nordisk A/S; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Berkeley, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.